ESCMID is part of the VALUE-Dx project, a European Public-Private Partnership to fight antimicrobial resistance through diagnostics.

This unique multidisciplinary consortium involves clinicians, microbiologists, health economists, social scientists, and industry, to help build the medical and economic case for rapid diagnostics as a public good in the fight against antibiotic resistance.

You can find an overview of the project here.

Latest news about the activities of the work packages are published here.


VALUE-Dx E-learning platform

The open access e-learning platform from VALUE-Dx hosts educational material (presentations, documents, handouts) to support the adoption of diagnostics in community care settings.

Find here the latest materials!

New Flyer on ADEQUATE

ADEQUATE  is a randomized controlled trial of Rapid Syndromic Diagnostic testing for enhancing the quality of antibiotic prescribing for community acquired acute respiratory tract infection (CA-ARTI) in Emergency Rooms in Europe.


There is a need to assess the impact of rapid syndromic diagnostic testing in patients with CA-ARTI presenting to Emergency Rooms on clinical decision making related to hospitalization and antibiotics prescribing. At the same time it must be determined whether the decisions guided by the rapid syndromic diagnostic testing results do not compromise patient safety.

Here you can find the new flyer outlining the criteria for adult site selection for ADEQUATE

WAAW Campaign

Since 2019, VALUE-Dx is participating to the World Antibiotic Awareness Week, the campaign held in November first initiated by WHO with the purpose of raising global awareness on proper handling of antibiotics and sharing good practices.


You can find more information about the initiatives carried out during last WAAW campaign by VALUE-Dx and its partners here.